This proposal will examine a newly described secretory protein, renalase, which appears to have a novel protective effect in acute pancreatitis (AP). AP has an incidence of up to 5/10,000, can cause death in 30% of those with severe disease, and is the most common reason for hospitalization for individuals with gastrointestinal disease. Since the disease is often caused by alcohol abuse and increases in incidence with age, it is frequently encountered in our Veteran population. Moreover, the risks for both developing AP and for severe disease are increased in chronic renal failure (CRF). Since CRF is common in our aging population of Veterans, it represents another relevant risk factor. We propose to study renalase, a serum protein that is produced in the kidneys and other tissues, that disappears from the serum with renal disease and other acute injuries. Renalase appears to have a potent protective pro-survival effect in the kidneys. We hypothesize that renalase will also have a protective role in AP and that decreases in renalase (serum and tissue) during some forms of injury, including acute pancreatitis, will result in more severe disease. We will examine the hypothesis with the following Specific Aims: 1) Determine whether serum renalase levels correlate with the presence of pancreatitis and its severity by examining its levels in sera and tissues from murine models of AP and in sera from patients with acute pancreatitis and controls; 2) Examine the effects of genetic deletion, peptide inhibition, and CRF on the severity of experimental murine AP; 3) Investigate whether exogenous recombinant renalase reduces severity of experimental acute pancreatitis in murine models and in human pancreatic acinar cells; 4) Determine whether the protective effects of renalase on pancreatitis-associated acinar cell injury is mediated by renalase activation of the plasma-membrane Ca2+ ATPase (PMCA) and Ca2+- extrusion. Mild and severe models of murine AP will be examined. Our preliminary data show the following: i) Serum renalase levels significantly decrease more than 50% within 2 hrs. after the initiation of murine AP and in humans with AP; ii) Genetic deletion of renalase results in a more severe phenotype of murine AP than wild- type controls; iii) Administering recombinant renalase reduces pancreatitis injury in isolated acinar cells and decreases the severity of murine AP in vivo whether given before or after disease onset; iv) Renalase binds to an isoform of the PMCA (PMCA4b) and enhances Ca2+-efflux from the pancreatic acinar cell; iv) PMCA inhibition enhances injury of acinar cells in pancreatitis. Our preliminary data firmly supports our hypothesis and demonstrates that we have the unique tools needed to complete the planned studies. The proposed work has the potential to provide a biomarker for pancreatitis and, more importantly, to characterize an attractive therapeutic target.

Public Health Relevance

Acute pancreatitis is an inflammatory disease that begins in the pancreas and can involve multiple organs when severe. About 25% of patients will have severe disease; up to 30% of those will die. The most common causes of acute pancreatitis are alcohol abuse and gallstones; renal failure is also risk factor for more severe disease. Since these conditions are more common in our Veterans, the proposed work has strong clinical. Using animal and cellular model of pancreatitis, we have discovered a new serum protein (renalase) that protects against pancreatitis, but it is absent in renal failure and reduced in acute pancreatitis. We propose to study renalase because it appears to have a strong protective role in pancreatitis and could represent a new therapy.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX003250-02
Application #
9280608
Study Section
Gastroenterology (GAST)
Project Start
2016-07-01
Project End
2020-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
VA Connecticut Healthcare System
Department
Type
DUNS #
039624291
City
West Haven
State
CT
Country
United States
Zip Code
06516
Kolodecik, Thomas R; Reed, Anamika M; Date, Kimie et al. (2017) The serum protein renalase reduces injury in experimental pancreatitis. J Biol Chem 292:21047-21059
Gorelick, Fred S; Lerch, Markus M (2017) Do Animal Models of Acute Pancreatitis Reproduce Human Disease? Cell Mol Gastroenterol Hepatol 4:251-262
Srinivasan, Padmanabhan; Thrower, Edwin C; Gorelick, Fred S et al. (2016) Inhibition of pancreatic acinar mitochondrial thiamin pyrophosphate uptake by the cigarette smoke component 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Am J Physiol Gastrointest Liver Physiol 310:G874-83
Gorelick, Fred S (2016) Advances in pancreatology: 2016. Curr Opin Gastroenterol :
Guo, Xiaojia; Hollander, Lindsay; MacPherson, Douglas et al. (2016) Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Sci Rep 6:22996
Chung, Chuhan; Gorelick, Fred S (2016) Targeting ?v Integrins in Pancreatic Fibrosis: Progress in Resolving the Scar. Cell Mol Gastroenterol Hepatol 2:405-406